Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03773965
Other study ID # 16278
Secondary ID I4V-MC-JAHX2017-
Status Recruiting
Phase Phase 3
First received
Last updated
Start date April 5, 2019
Est. completion date December 18, 2030

Study information

Verified date April 2024
Source Eli Lilly and Company
Contact There may be multiple sites in this clinical trial. 1-877-CTLILL
Phone 1-317-615-4559
Email ClinicalTrials.gov@lilly.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.


Recruitment information / eligibility

Status Recruiting
Enrollment 190
Est. completion date December 18, 2030
Est. primary completion date December 18, 2030
Accepts healthy volunteers No
Gender All
Age group 1 Year to 18 Years
Eligibility Inclusion Criteria: - Participants must have completed a previous study of baricitinib for the treatment of JIA. Exclusion Criteria: - Participants must not have had a permanent discontinuation of baricitinib in the prior study. - Participants must have not developed an allergy to baricitinib.

Study Design


Intervention

Drug:
Baricitinib
Administered orally.

Locations

Country Name City State
Argentina Hospital General de Niños Dr. Pedro de Elizalde Buenos Aires
Argentina Instituto CAICI SRL Rosario Santa Fe
Argentina Centro de Investigaciones Médicas Tucuman San Miguel de Tucuman Tucumán
Australia Royal Children's Hospital Melbourne Victoria
Australia Perth Children's Hospital Perth Western Australia
Australia The Children's Hospital at Westmead Westmead New South Wales
Austria Landeskrankenhaus Bregenz Bregenz Vorarlberg
Austria Medizinische Universität Wien Vienna Wien
Belgium Cliniques universitaires Saint-Luc Brussels Bruxelles-Capitale, Région De
Belgium UZ Gent Gent Oost-Vlaanderen
Belgium UZ Leuven Leuven Vlaams-Brabant
Brazil Faculdade de Medicina da UNESP Botucatu São Paulo
Brazil Instituto da Crianca do Hospital das Clinicas da FMUSP Sao Paulo São Paulo
Brazil IPITEC São Paulo
Brazil Universidade Federal de Sao Paulo São Paulo
China Beijing Children's hospital, Capital Medical University Beijing Beijing
China Beijing Peking Union Medical College Hospital Beijing Beijing
China The Children's Hospital of Chongqing Medical University Chongqing Chongqing
China The Second Affiliated Hospital Chongqing Medical University Chongqing Chongqing
China Childrens Hospital of Nanjing Medical University Nanjing Jiangsu
China Children's Hospital of Soochow University Suzhou Jiangsu
Czechia Detska nemocnice FN Brno Brno Brno-mesto
Czechia Fakultni nemocnice Olomouc Olomouc
Czechia Fakultni nemocnice Motol Praha Praha 5
Czechia Vseobecna fakultni nemocnice v Praze Praha 2
Denmark Aarhus Universitetshospital, Skejby Aarhus Midtjylland
Denmark Rigshospitalet Copenhagen Hovedstaden
France Hospices Civils de Lyon - Hôpital Femme Mère Enfant Bron Rhône-Alpes
France Hôpitaux Universitaires Paris Sud - Hôpital Bicêtre Le Kremlin-Bicêtre Paris
France Centre Hospitalier Universitaire de Nîmes - Hôpital Universitaire Carémeau Nîmes Gard
France Hôpital Universitaire Necker Enfants Malades Paris
France Centre Hospitalier Universitaire de Poitiers Poitiers Vienne
Germany Charité Campus Virchow-Klinikum Berlin
Germany Helios Klinikum Berlin-Buch Berlin
Germany Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari Hamburg
Germany Universitätsklinikum Heidelberg Heidelberg Baden-Württemberg
Germany Asklepios Klinik Sankt Augustin Sankt Augustin Nordrhein-Westfalen
Germany Universitaetsklinikum Tuebingen Tuebingen Baden-Württemberg
India Sri Ramachandra MedicaL College & Research Institute Chennai Tamil Nadu
India Sir Ganga Ram Hospital New Delhi Delhi
India Christian Medical College Vellore Vellore Tamil Nadu
Israel Rambam Health Care Campus Haifa ?eifa
Israel Meir Medical Center Kfar Saba HaMerkaz
Israel Schneider Children's Medical Center Petah Tikva HaMerkaz
Israel Sheba Medical Center Ramat Gan HaMerkaz
Italy Azienda Ospedaliera Spedali Civili di Brescia Brescia
Italy Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti Chieti
Italy IRCCS Istituto Giannina Gaslini Genova Liguria
Italy Centro Specialistico Ortopedico Traumatologico Gaetano Pini - CTO Milano Lombardia
Italy Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano Lombardia
Italy University of Naples Federico II Napoli Campania
Italy Azienda di Rilievo Nazionale e Alta Specializzazione Civico Di Cristina Benfratelli Palermo Sicilia
Italy Ospedale Infantile Burlo Garofolo Trieste
Japan Tokyo Medical And Dental University Medical Hospital Bunkyo Tokyo
Japan Chiba Children's Hospital Chiba
Japan Kanazawa University Hospital Kanazawa Ishikawa
Japan Niigata University Medical & Dental Hospital Niigata
Japan Saitama Children's Medical Center Saitama-shi Saitama
Japan Miyagi Children's Hospital Sendai Miyagi
Japan Tokyo Women's Medical University Hospital Shinjuku-ku Tokyo
Japan Osaka Medical and Pharmaceutical University Hospital Takatsuki Osaka
Japan St. Luke's International Hospital Tokyo
Japan Kanagawa Children's Medical Center Yokohama Kanagawa
Japan Yokohama City University Hospital Yokohama Kanagawa
Mexico Investigacion y Biomedicina de Chihuahua Chihuahua
Mexico Instituto de Investigaciones Clínicas para la Salud Durango
Mexico Crea de Guadalajara Guadalajara Jalisco
Mexico Clinstile, S.A. de C.V. Mexico Distrito Federal
Mexico Hospital Universitario "Dr. Jose Eleuterio Gonzalez" Monterrey Nuevo León
Poland Wojewódzki Specjalistyczny Szpital Dzieciecy im. sw. Ludwika w Krakowie Krakow Malopolskie
Poland Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi Lódz Lódzkie
Poland Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji Warsaw Mazowieckie
Russian Federation Federal State Budgetary Scientific Institution Research Institute Rheumatology named after V.A.Nasonova Moscow Moskva
Russian Federation Scientific Center of Children's Health Moscow Moskva
Spain Hospital Sant Joan de Déu Esplugues de Llobregat Barcelona [Barcelona]
Spain Hospital Infantil Universitario Niño Jesús Madrid Madrid, Comunidad De
Spain Hospital Universitario La Paz Madrid
Spain Hospital Universitario Ramón y Cajal Madrid Madrid, Comunidad De
Spain Hospital Universitario Virgen Del Rocio Sevilla
Spain Hospital Universitari i Politecnic La Fe València
Turkey Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine Istanbul
Turkey 9 Eylul University Hospital Izmir
United Kingdom Bristol Royal Hospital for Children Bristol Bristol, City Of
United Kingdom Alder Hey Children's Hospital Liverpool England
United Kingdom Great Ormond Street Hospital For Children NHS Foundation Trust London London, City Of
United Kingdom University College Hospital - London London Greater London
United Kingdom Oxford University Hospitals - Nuffield Orthopaedic Centre Oxford Oxfordshire
United Kingdom Sheffield Children's Hospital Sheffield

Sponsors (1)

Lead Sponsor Collaborator
Eli Lilly and Company

Countries where clinical trial is conducted

Argentina,  Australia,  Austria,  Belgium,  Brazil,  China,  Czechia,  Denmark,  France,  Germany,  India,  Israel,  Italy,  Japan,  Mexico,  Poland,  Russian Federation,  Spain,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with One or More Serious Adverse Event(s) (SAEs) Number of participants with one or more SAEs Baseline through Week 264
Primary Number of Participants with Permanent Investigational Product Discontinuations Number of participants with permanent investigational product discontinuations Baseline through Week 264
Secondary Proportion of Participants Achieving Pediatric American College of Rheumatology 30 Responder Index (PedACR30) Proportion of participants achieving PedACR30 Week 264
Secondary Proportion of Participants who have Disease Flare Proportion of participants who have disease flare Baseline through Week 264
Secondary Proportion of Participants with Inactive Disease Proportion of participants with inactive disease Week 264
Secondary Proportion of Participants with Minimal Disease Activity Proportion of participants with minimal disease activity Week 264
Secondary Proportion of Participants in Remission Proportion of participants in remission Week 264
Secondary Change from Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS27) Change from baseline of originating study in JADAS27 Baseline, Week 264
Secondary Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item Change from baseline in arthritis-related pain severity as measured by the CHAQ pain VAS item Baseline, Week 264
Secondary Change from Baseline in Psoriasis Area and Severity Index (PASI) Change from baseline in PASI Baseline, Week 264
Secondary Change from Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index Change from baseline in SPARCC enthesitis index Baseline, Week 264
Secondary Change from Baseline in Juvenile Spondyloarthritis Disease Activity Index (JSpADA) Change from baseline in JSpADA Baseline, Week 264
Secondary Change from Baseline in Immunoglobulin Levels Change from baseline in immunoglobulin levels Baseline, Week 264
Secondary Change from Baseline in Immunophenotyping (T Cells) Change from baseline in immunophenotyping (T Cells) Baseline, Week 264
Secondary Change of Immunoglobulin G (IgG) Titers Change of IgG titers Pre-Vaccination to 12 Weeks Post-Vaccination
See also
  Status Clinical Trial Phase
Completed NCT02776735 - An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Phase 2
Active, not recruiting NCT03092427 - Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA) N/A
Not yet recruiting NCT05545098 - MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA
Not yet recruiting NCT03833609 - Yoga and Aerobic Dance for Pain Management in Juvenile Idiopathic Arthritis N/A
Completed NCT02524340 - Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference
Recruiting NCT01434082 - Sleep Patterns in Children With and Without Juvenile Idiopathic Arthritis N/A
Completed NCT04671524 - The Effect of Improvement in Function on Foot Pressure, Balance and Gait in Children With Upper Extremity Affected N/A
Recruiting NCT04167488 - Assessment of Physical Activity Among Juvenile Idiopathic Arthritis Children Performed With Actigraphy N/A
Recruiting NCT04205500 - Treatment With Specific Carbohydrate Diet in Children With Juvenile Idiopathic Arthritis N/A
Terminated NCT01694264 - Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα Phase 3
Completed NCT02824978 - Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?
Active, not recruiting NCT03841357 - Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA) Phase 3
Completed NCT03833271 - The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary Early Phase 1
Completed NCT01455701 - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) Phase 1
Completed NCT05031104 - Low-energy Laser Applications in Patients With Juvenile Idiopathic Arthritis N/A
Not yet recruiting NCT01436019 - Study of Antibodies to Anti-TNF Agents in Juvenile Idiopathic Arthritis N/A
Recruiting NCT05609630 - Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. Phase 3
Recruiting NCT05696340 - Access to Pediatric Rheumatology Centers for JIA Patients: Factors Associated With Time to Access Pediatric Rheumatology Centers
Recruiting NCT05545839 - Transition to Adulthood Through Coaching and Empowerment in Rheumatology N/A
Completed NCT05436301 - Turkish Validity and Reliability of Pain Catastrophizing Scale-Child (PCS-C)